Drug Profile
Napabucasin - Sumitomo Pharma America
Alternative Names: BB 608; BBI 608 DP1; BBI 608 DP2A; BBI-608; DP1; DP2A; GB-201Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Boston Biomedical
- Developer 1Globe Biomedical; Boston Biomedical; Sumitomo Pharma; Sumitomo Pharma America
- Class Antineoplastics; Furans; Naphthoquinones; Small molecules
- Mechanism of Action Beta catenin inhibitors; Cell death stimulants; STAT3 transcription factor inhibitors; Stem cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- Phase I/II Gastrointestinal cancer; Glioblastoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- No development reported Haematological malignancies
- Discontinued Gastric cancer; Oesophageal cancer; Pancreatic cancer
Most Recent Events
- 28 Apr 2023 Discontinued - Phase-III for Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO)
- 28 Apr 2023 Discontinued - Phase-III for Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium (PO)
- 28 Apr 2023 Discontinued - Phase-III for Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO)